Market share charts for femoral artery closure devices looked like a roller coaster through Q3 2000, with each quarter producing a new market leader--Datascope, St. Jude Medical, and Perclose. Interventional cardiologists, whose views on device utilization levels and product lines varied, helped explain the market share movements, among other things noting the introduction of smaller, six French devices that led to the success of St. Jude, with Angio-seal and Duet. Most physicians agreed that while experimentation with different devices at this early stage of the market's development was leading to strong sales for all products, most hospitals will, over time, reduce redundancy in the product line and likely will end up carrying only two brands.
According to new data, the market share charts for femoral
artery closure devices looked like a roller coaster through the
first three quarters of this year, with each quarter producing a
new market leader. The data was provided by MD Data Direct, an
Internet based market research and data gathering firm which tracks
actual product usage in several cardiovascular categories.
According to MD Data's data, compiled from more than 14,600 interventional cardiology cases performed at 40 hospitals around the country,...
Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.
While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.
